The Day In Review: Genentech, Inc. Hits Its Numbers

October 10, 2006 – After the closing bell, Genentech released very positive Q3 numbers, showing profit rose 58% and revenues increased 36%; Corautus released a full analysis of the failed trial of VEGF-2; Cerus began a Phase I trial of CRS-100, an immunotherapy for cancer; Momenta began a Phase I test of its anticoagulant; Theravance released more details from its Phase III tests of telavancin; GenVec will receive anther $3.6 million from the NIH for an HIV vaccine; Inspire will begin a Phase II test of epinastine, a therapy for rhinitis; and EpiCept asked for European approval of leukemia drug Ceplene. At the close, the Centient Biotech 200™ was 17 points lower at 3929, a loss of .43%. More details...

Back to news